- Aileron Therapeutics (NASDAQ:ALRN) announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in p53-mutated breast cancer showed severe neutropenia (Grade 4) and alopecia (hair loss).
- The primary endpoint of the Phase 1b open-label trial was evaluating ALRN-6924 in patients with breast cancer receiving neoadjuvant or adjuvant treatment with docetaxel, doxorubicin, and cyclophosphamide, or “TAC” chemotherapy, was the duration and incidence of severe neutropenia in cycle 1.
- Related: Aileron Shares Fall After Early Data From Chemoprotective Agent In Lung Cancer Setting.
- The incidence of chemotherapy-induced alopecia (hair loss) was a secondary endpoint.
- Based on these findings, Aileron has decided to terminate the Phase 1b breast cancer trial and further development of ALRN-6924.
- Aileron also announced that it is exploring various strategic alternatives and has engaged Ladenburg Thalmann & Co Inc as a strategic advisor for this process.
- Aileron will reduce its remaining workforce from 9 to 3 full-time employees in the coming weeks. The company plans to retain the remaining employees to assist in executing the strategic alternatives review process.
- Price Action: ALRN shares are down 43.70% at $1.32 on the last check Tuesday.
Odyssey Health Gains Shareholder Approval for Asset Sale With Oragenics; Odyssey Received Second $500K Payment From Oragenics On Dec. 11
Odyssey Health, Inc. (OTCOB:ODYY), a company focused on developing unique, life-enhancing medical products including a drug treatment intended to treat concussion, announces that it has received stockholder approval for
